TLR-2 agonist Pam3CSK4 has no therapeutic effect on visceral leishmaniasis in BALB/c mice and may enhance the pathogenesis of the disease

In this study, TLR-2 agonist Pam3CSK4 showed no therapeutic effect on visceral leishmaniasis in BALB/c mice and might enhance the pathogenesis of the disease possibly due to the down-regulation of several immune-related pathways, which can improve our understanding of the role of TLR-2 in both treatment and vaccine development.PMID:37562277 | DOI:10.1016/j.imbio.2023.152725

Source: Immunobiology - August 10, 2023 Category: Allergy & Immunology Authors: Xuechun Liao Jinlei He Ruanyan Wang Jianhui Zhang Shulan Wei Yuying Xiao Qi Zhou Xiaoting Zheng Zheying Zhu Zhiwan Zheng Jiao Li Zheng Zeng Dali Chen Jianping Chen Source Type: research